Publications by authors named "J R Day"

Single nucleus RNA sequencing (snRNA-seq) technology offers unprecedented resolution for studying cell type-specific gene expression patterns. However, snRNA-seq poses high costs and technical limitations, often requiring the pooling of independent biological samples and loss of individual sample-level data. Deconvolution of sample identity using inherent features would enable the incorporation of pooled barcoding and sequencing protocols, thereby increasing data throughput and analytical sample size without requiring increases in experimental sample size and sequencing costs.

View Article and Find Full Text PDF

Introduction: Chronic hepatitis D virus (HDV) is associated with rapid progression to severe liver disease. Co-infection with HDV and hepatitis B virus is likely underdiagnosed due to challenges in diagnostic test availability and standardization. With new HDV antiviral options, HDV RNA quantification is essential for understanding the patient response to treatment.

View Article and Find Full Text PDF
Article Synopsis
  • X-linked hypophosphataemia (XLH) is a chronic disorder that leads to bone deformities and affects quality of life due to symptoms like pain and fatigue.
  • Burosumab, a treatment for XLH, was approved for adults in 2020 and has shown positive effects in patients.
  • Three adults with ongoing XLH symptoms reported significant improvements in various aspects of their health, including pain relief, increased mobility, and better overall well-being after receiving burosumab treatment.
View Article and Find Full Text PDF

Fibre optic probe based Raman spectroscopy can deliver molecular compositional analysis of a range of diseases. However, some biological tissues exhibit high levels of fluorescence which limit the utility of the technique, particularly when the fluorescence induces CCD etaloning, which can be particulalry hard to remove in subsequent analysis. Furthermore, use of fibre probes can result in silica signals superimposed on the biological Raman signals.

View Article and Find Full Text PDF
Article Synopsis
  • Progression of disease within 24 months of initial immunochemotherapy (POD24) in follicular lymphoma (FL) is linked to worse patient outcomes, and there is currently no standard treatment for these patients.
  • A study of 256 FL patients with POD24 revealed diverse treatment approaches, with bendamustine-rituximab patients mostly receiving R-CHOP therapy and R-CHOP patients opting for aggressive salvage therapy.
  • The overall response rate to treatments after POD24 was 66%, with a complete response rate of 40%, while factors like age over 70 and high-risk FLIPI scores worsened overall survival outcomes (73% at 5 years).
View Article and Find Full Text PDF